Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE (Vamorolone) in India
Santhera Pharmaceuticals announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE (vamorolone) in India, for...
ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy
ITF Therapeutics affiliate of Italfarmaco, today announced publication of positive long-term safety and efficacy data for Duvyzat (Givinostat) as a treatment for Duchenne muscular...
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
Keros Therapeutics today announced the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dystrophy...
Agamree to be sold in United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain starting in 2026
Santhera Pharmaceuticals announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, the...
Santhera Secures Agreement with GEN for the Distribution of AGAMREE (Vamorolone) in Turkiye
Santhera Pharmaceuticals announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and...